Eton Pharmaceuticals, Inc. ETON Debt-to-equity

Debt-to-equity at other companies

HRO

HarrowHROW

20.3×+11.2×

XER

Xeris Biopharma Holdings, Inc.XERS

19.9×—

ANI PharmaceuticalsANIP

0.5×-0.2×

Zevra Therapeutics, Inc.ZVRA

0×-0.5×

Ultragenyx PharmaceuticalRARE

3.7×—

Rigel PharmaceuticalsRIGL

0.2×+0.1×

FAQ

What is Eton Pharmaceuticals, Inc.'s debt-to-equity?

Eton Pharmaceuticals, Inc. (ETON) reported debt-to-equity of 1× in Q1 2026.

How has Eton Pharmaceuticals, Inc.'s debt-to-equity changed year-over-year?

Eton Pharmaceuticals, Inc.'s debt-to-equity decreased by 17.2% year-over-year, from 1.2× to 1×.

What is the long-term trend for Eton Pharmaceuticals, Inc.'s debt-to-equity?

Over 5 years (2020 to 2025), Eton Pharmaceuticals, Inc.'s debt-to-equity has grown at a 22.6% compound annual growth rate (CAGR), from 0.4× to 1.2×.

What does debt-to-equity mean?

Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.